DEF: Terns Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting

Terns Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders online on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Terns Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders online on June 11, 2025, at 2:00 p.m. Pacific Time.
• The meeting will cover the election of three Class I directors, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and any other business that may properly come before the meeting.
• Stockholders of record as of April 14, 2025, are eligible to vote.
• The board of directors recommends voting for the election of the director nominees and for the ratification of Ernst & Young LLP.
• The company had 87,336,770 shares of common stock outstanding as of the record date.
• To be considered for inclusion in next year's proxy materials, stockholder proposals must be submitted by December 30, 2025.
• The company is still considered an emerging growth company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, so the sentiment is neutral to positive. It indicates the company is fulfilling its corporate governance responsibilities.

Positives

• The Annual Meeting will be held online to allow greater participation and improved communication and provide cost savings for our stockholders and the Company.
• The board of directors has determined that all members of the audit committee are independent under the Nasdaq Listing Rules and Rule 10A-3(b)(1) of the Exchange Act.

Future Outlook

The company will remain an emerging growth company until the earlier of December 31, 2026, meeting certain revenue thresholds, or meeting certain market capitalization thresholds.

Management Comments

• On behalf of the board of directors, I would like to express our appreciation for your interest in Terns, said Amy Burroughs, Chief Executive Officer and Director.

Industry Context

This is a standard annual meeting announcement, typical for publicly traded companies to fulfill their corporate governance obligations.

Comparison to Industry Standards

• The director compensation structure is similar to other biopharmaceutical companies of comparable size.
• The audit fees paid to Ernst & Young LLP are within the typical range for companies of similar complexity and revenue.
• The corporate governance practices, such as having independent directors and audit, compensation, and nominating committees, align with Nasdaq requirements and industry best practices.

Management Changes

Stakeholder Impact

• Shareholders are asked to vote on key company matters.
• The election of directors and ratification of the accounting firm impacts the company's governance and financial oversight.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 11, 2025.
• The company will file a Current Report on Form 8-K within four business days after the Annual Meeting to announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Ernst & Young, Accounting Firm, Corporate Governance, Terns Pharmaceuticals